Q4 2024 Earnings Call Transcript February 12, 2025 Mineralys Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –– ...

In a report released today, Richard Law CFA from Goldman Sachs maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research ...

Q4 2024 Management View CEO Jon Congleton highlighted the company's focus on advancing its pivotal trials for lorundrostat, targeting dysregulated aldosterone in patients with uncontrolled and ...

Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) shot up 4% during trading on Friday .The stock traded as high as $13.43 and last traded at $13.39. 9,138 shares were traded ...

I believe Mineralys Therapeutics has a promising candidate with Lorundrostat for hypertension, CKD, and OSA. It should report more key pivotal clinical data this year. MLYS has several Phase 2 and ...

Mineralys Therapeutics, Inc. (MLYS) stock price is 10.30 and Mineralys Therapeutics, Inc. (MLYS) 10-day simple moving average is 10.02. Mineralys Therapeutics, Inc. (MLYS) stock price is 10.30 and ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease ...

Ericsson Posts Weak Results, Joins East West Bancorp And Other Big Stocks Moving Lower In Friday's Pre-Market Session ...

Jon Congleton; Chief Executive Officer, Director; Mineralys Therapeutics Inc. David Rodman; Chief Medical Officer ...

RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has... ByInvesting.com ...